COVID-19 in Kidney Transplant Recipients: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Virology
Contributor:
Smaragdi Marinaki
,
Stathis Tsiakas
,
Maria Korogiannou
,
Konstantinos Grigorakos
,
Vassilios Papalois
,
Ioannis Boletis

COVID-19 has posed a significant challenge to physicians and health care systems worldwide. Data regarding kidney transplant recipients are still limited. This review provides insight into the clinical characteristics, immunosuppression management, and treatment outcomes of kidney transplant recipients with COVID-19 infection.

  • COVID-19
  • kidney transplant recipients
  • immunosuppression
  • outcomes

1. Introduction

As the first wave of the coronavirus disease 2019 (COVID-19) pandemic is continuing with different effects in different countries, our knowledge about disease features and outcomes of this novel coronavirus in the general population has grown substantially [1].

Kidney transplant (KTx) recipients have been recently classified by the Center for Disease Control and Prevention (CDC) as a high-risk group for severe COVID-19 [2]. Emerging evidence suggests 10-fold higher rates of early case fatality rate (CFR) in transplanted patients compared to that in the general population (GP) [3,4], due to the immunocompromised status resulting in impaired immunological response to pathogens [5] and to the almost universal presence of comorbidities [6,7].

The body of literature regarding COVID-19 infection in kidney transplantation is growing every day; however, it comprises mostly case reports, small case series, and small cohorts.

There is a broad variation in studies among different countries across the globe. The reported KTx recipients are heterogeneous in terms of race, ethnicity, time from transplantation, and baseline status at the time of COVID-19 infection. 

We performed a systematic review of all studies reporting on kidney transplant recipients with confirmed COVID-19 infection.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92]

2. Patients’ Demographics and Baseline Characteristics

The mean and median age of the 169 patients, for whom individual patient data were available, were 55 ± 15 years and 55 years (range 21–80) respectively. The reported median age from available aggregated data ranged from 57 to 60 years. There was a male predominance of 67%.
The majority of KTx recipients (74%) had received a deceased donor transplant (DBD in 95% of cases), while 26% had been transplanted from a living donor. In 156 cases, the donor source was not reported.
Seven out of 420 patients (2%) were multiple organ transplant recipients: 2 had received liver and kidney, 2 had received heart and kidney, and 3 had received pancreas and kidney, respectively.
From the total cohort, only 2% of patients had undergone subsequent kidney transplantations. Median time from KTx to COVID-19 infection was 6.5 years (range 0–33) while 23% of the patients were transplanted for less than one year.
The majority of patients (81%) suffered from hypertension (HTN), while only 12% had no comorbidities. The second most frequent associated medical condition was diabetes mellitus (DM) (36%), followed by cardiovascular disease (CVD) (21%), obesity (OB) (15%), chronic obstructive pulmonary disease (COPD) (5%), malignancy (4%), and chronic viral infection (2%).
Out of 162 patients with comorbidities, 41% had one, 29% had two, and 18% suffered from three comorbidities.
Baseline renal function was relatively well-preserved with a median serum creatinine of 1.47 mg/dL in 91 patients. Baseline eGFR was assessed in a few studies (16 out of 63) with a mean of 40 ± 23 mL/min/1.73 m2. The median peak serum creatinine during hospitalization was 2.2 mg/dL (range 0.62–10.94) and returned to 1.4 mg/dL at discharge.
The patients’ clinical features and outcomes as well as management strategies are depicted in Table 3.

Table 3. Demographic and baseline characteristics, clinical outcomes, and treatment of kidney transplant recipients with coronavirus disease 2019 (COVID-19) infection.

Demographics  
Age (years, median) (n = 169) 55 (21–80)
Gender (male) 276/415 (67%)
Type of donor (deceased donor) 195/264 (74%)
Multiple organ transplant recipients 7/420 (2%)
Repeat KTx 7/420 (2%)
Time from KTx (years, median) 6.5 (0–33)
Time from KTx ≤ 1 year 48/209 (23%)
Comorbidities (n = 326)  
HTN 81%
DM 36%
CVD 21%
Obesity 15%
COPD 5%
Malignancy 4%
Chronic viral infection 2%
Renal function  
Baseline sCr (mg/dL, median) (n = 91) 1.47 (0.62–5.09)
Peak sCr during hospitalization (mg/dL, median) (n = 74) 2.17 (0.62–10.94)
sCr at discharge (median) (n = 58) 1.45 (0.29–6.45)
Baseline Immunosuppressive regimen  
MPA/AZA + CNI ± CS 136/186 (73%)
Hospital admission (n = 420) 93%
Duration of hospitalization (days, median) (n = 104) 16 (1–100)
Admission to ICU 118/391 (30%)
Duration of ICU stay (days, median) (n = 32) 8.5 (1–34)
Type of Ventilation  
NIV 27/379 (7%)
IMV 88/379 (23%)
ARDS 175/391 (45%)
AKI 150/345 (44%)
RRT 34/150 (23%)
Immunosuppression management  
IS discontinuation 66/212 (31%)
IS reduction 97/357 (27%)
Switch TAC or mTORi to CsA 24/358 (7%)
CNI tapering 65/204 (32%)
CNI withdrawal 118/204 (58%)
Antimetabolite withdrawal 227/250 (91%)
COVID-19 treatment  
Antivirals 123/414 (30%)
Lopinavir/Ritonavir 94/123 (76%)
HCQ 320/409 (78%)
Antibiotics 290/399 (73%)
Azithromycin 155/290 (53%)
CS (IV bolus or Dexamethasone) 83/331 (25%)
Anti-IL agents 59/213 (28%)
IV immunoglobulins 35/415 (8%)
Major outcomes  
Death 93/420 (22%)
Discharge 232/391 (59%)

3. Major Clinical Outcomes after COVID-19 Infection

The infection rate in our study ranged from 0.27% to 1.67% and was calculated in those studies where the number of the total cohort of KTx recipients was available.

Of the total cohort, 93% of patients were hospitalized. The median duration of hospitalization was 16 days (range 1–100). From 391 hospitalized patients, 118 (30%) were admitted to the intensive care unit (ICU). In 32 out of 118 patients, the median duration of the ICU stay was 8.5 days (range 1–34). Non-invasive mechanical ventilation (NIV) was applied to 7% and invasive mechanical ventilation (IMV) to 23% of patients. Acute respiratory distress syndrome (ARDS) was reported in (175/391) 45% of patients. A substantial proportion of patients, (150/345) 44% developed acute kidney injury (AKI), with the need for renal replacement therapy (RRT) reported in 23%. Death was recorded in (93/420) 22% of patients. Most patients, (232/391) 59% were discharged; 29 patients remained hospitalized when the studies were published, 14 of whom were still in the ICU.

Case fatality rates in the case series including more than ten patients ranged from 6% up to 67%.

4. Baseline Immunosuppression and Modifications during COVID-19 Infection

The most frequently applied immunosuppressive regimen at baseline consisted of a calcineurin inhibitor (CNI), an antimetabolite, and corticosteroids (CS) in 73% of patients.

In total, 64% (147/230) of patients were receiving tacrolimus (TAC), 10% (18/176) cyclosporine (CsA), 68% (217/319) mycophenolic acid (MPA), 14% (26/184) everolimus, 4% (9/211) azathioprine (AZA), and a minority (<2%) of patients other agents such as belatacept, mizoribine, or leflunomide.

Overall, immunosuppression was reduced in 27% (97/357), discontinued in 31% (66/212), and remained unchanged in 5% (14/275) of patients. The most frequently discontinued drug was the antimetabolite in 91% (227/250) of patients. Calcineurin inhibitors were reduced in 32% (65/204) and discontinued in 58% (118/204) of patients. Switch from TAC or mammalian target of rapamycin inhibitor (mTORi) to CsA occurred in 7% (24/358) of patients. The mTORi was reduced in 7% (2/27) and discontinued in 67% (18/27) of cases.

5. COVID-19-Targeted Therapies

The main agents used for COVID-19 infection were antivirals, antibiotics, hydroxychloroquine (HCQ), anti-IL monoclonal antibodies, and steroid boluses. In total, 30% (123/414) of patients received antivirals. The most frequently used antiviral was lopinavir/ritonavir, administered to 76% (94/123) of those. Other antivirals included darunavir/ritonavir (13%), ritonavir-darunavir/lopinavir (4%), oseltamivir or arbidol (11%), umifenovir (7%), and darunavir/cobicistat (2%).Hydroxychloroquine was administered to 78% (320/409) of patients. The majority of patients (73%, 290/399) received antibiotics: azithromycin was administered to 53% (155/290) and other broad-spectrum antibiotics to 17% (50/290) of cases. Corticosteroid (CS) boluses or dexamethasone were used in 25% (83/331) of patients. Anti-IL agents were introduced in 28% (59/213) of patients with more severe illness; tocilizumab was the preferred agent in 56 of 59 patients.Less frequently used agents were immunoglobulin in 8%, colchicine in 0.5%, interferon in 0.5%, and leronlimab in 1.4% of patients.

In conclusion, the main finding of our analysis is the high rate of all major adverse outcomes among hospitalized patients with COVID-19 infection.

This entry is adapted from the peer-reviewed paper 10.3390/jcm9092986

References

  1. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020; 92: 548-51.
  2. Prevention. CfDCa. People Who Are at Higher Riskfor Severe Illness:. People with Underlying Medical Conditions, Immunocompromised state (weakened immune system) from solid organ transplant https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditionshtml?CDC_AA_refVal=https%3A%2F%2Fwwwcdcgov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-riskhtml, 2020, last accessed 30/7/2020.
  3. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and Kidney Transplantation. N Engl J Med, 2020: 2475-7.
  4. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020; 20: 1800-8.
  5. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357: 2601-14.
  6. Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020; 20: 1819-25.
  7. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020; 97: 1083-8.
  8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097.
  9. Akdur A, Karakaya E, Ayvazoglu Soy EH, et al. Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience. Exp Clin Transplant. 2020; 18: 270-4.
  10. Allam SR, Dao A, Madhrira MM, et al. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Transpl Infect Dis, 2020: e13326.
  11. Bartiromo M, Borchi B, Botta A, et al. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis. 2020: e13286.
  12. Billah M, Santeusanio A, Delaney V, Cravedi P, Farouk SS. A catabolic state in a kidney transplant recipient with COVID-19. Transpl Int, 2020.
  13. Bussalino E, De Maria A, Russo R, Paoletti E. Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1922-4.
  14. Chen S, Yin Q, Shi H, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020; 20: 1869-74.
  15. Cheng DR, Wen JQ, Liu ZZ, Lv TF, Chen JS. Coronavirus disease 2019 in renal transplant recipients: report of two cases. Transpl Infect Dis. 2020: e13329.
  16. Chenna A, Konala VM, Gayam V, Naramala S, Adapa S. Coronavirus Disease 2019 (COVID-19) in a Renal Transplant Patient. Cureus. 2020; 12.
  17. Dirim AB, Demir E, Ucar AR, et al. Fatal SARS-CoV-2 infection in a renal transplant recipient. CEN Case Rep. 2020: 1-4.
  18. Fontana F, Alfano G, Mori G, et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1902-6.
  19. Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant, 2020: 1941-3.
  20. Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1875-8.
  21. Hasan Ahmad S, Smith R, Camilleri B. Belatacept, kidney transplantation and COVID-19: successful management of the first reported case within the United Kingdom. Clin Transplant. 2020: e14026.
  22. Hsu JJ, Gaynor P, Kamath M, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1911-5.
  23. Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant. 2020; 20: 1879-81.
  24. Jiang J, Miao Y, Zhao Y, et al. Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications. Clin Transplant. 2020: e14025.
  25. Kates OS, Fisher CE, Stankiewicz-Karita HC, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1885-90.
  26. Kemmner S, Guba MO, Schönermarck U, Stangl M, Fischereder M. Cyclosporine as a preferred calcineurin inhibitor in renal allograft recipients with COVID-19 infection. Kidney Int. 2020; 98: 507-8.
  27. Kim Y, Kwon O, Paek JH, et al. Two distinct cases with COVID-19 in kidney transplant recipients. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020.
  28. Kocak B, Arpali E, Akyollu B, et al. A Case Report of Oligosymptomatic Kidney Transplant Patients with COVID-19: Do They Pose a Risk to Other Recipients? Transplant Proc. 2020.
  29. Kolonko A, Dudzicz S, Wiecek A, Król R. COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation. Transpl Infect Dis. 2020: e13381.
  30. Kumar RN, Tanna SD, Shetty AA, Stosor V. COVID-19 in an HIV-positive Kidney Transplant Recipient. Transpl Infect Dis. 2020: e13338.
  31. Lauterio A, Valsecchi M, Santambrogio S, et al. Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. Transpl Infect Dis. 2020: e13334.
  32. Machado DJB, Ianhez LE. COVID-19 pneumonia in kidney transplant recipients-Where we are? Transpl Infect Dis. 2020: e13306.
  33. Man Z, Jing Z, Huibo S, Bin L, Fanjun Z. Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia. Am J Transplant, 2020.
  34. Marx D, Moulin B, Fafi-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant, 2020: 1944-6.
  35. Meziyerh S, Zwart TC, van Etten RW, et al. Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. Am J Transplant. © 2020 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1896-901.
  36. Namazee N, Mahmoudi H, Afzal P, Ghaffari S. Novel Corona Virus 2019 pneumonia in a kidney transplant recipient. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020.
  37. Ning L, Liu L, Li W, et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1864-8.
  38. Seminari E, Colaneri M, Sambo M, et al. SARS Cov-2 infection in a renal-transplanted patient: A case report. Am J Transplant. 2020; 20: 1882-4.
  39. Serrano OK, Kutzler HL, Rochon C, et al. Incidental COVID-19 in a heart-kidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS-CoV-2 immune response. Transpl Infect Dis. © 2020 Wiley Periodicals LLC., 2020: e13367.
  40. Shingare A, Bahadur MM, Raina S. COVID-19 in recent kidney transplant recipients. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020.
  41. SJ. A, Singh J, Jesus MD, Lance J. Early Use of Tocilizumab in Respiratory Failure Associated with Acute COVID -19 Pneumonia in Recipients with Solid Organ Transplantation. IDCases. 2020: e00888.
  42. Suwanwongse K, Shabarek N. Fatal Outcome in a Kidney-Pancreas Transplant Recipient With COVID-19. Cureus. 2020; 12.
  43. Tantisattamo E, Reddy UG, Duong DK, et al. Hyponatremia: A Possible Immuno-Neuroendocrine Interface with COVID-19 in a Kidney Transplant Recipient. Transpl Infect Dis. 2020: e13355.
  44. Thammathiwat T, Tungsanga S, Tiankanon K, et al. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient. Transpl Infect Dis. 2020: e13388.
  45. Velioglu A, Tuglular S. Care of Asymptomatic SARS-CoV-2 positive Kidney Transplant Recipients. Transpl Int. 2020.
  46. Wang J, Li X, Cao G, Wu X, Wang Z, Yan T. COVID-19 in a Kidney Transplant Patient. Eur Urol. 2020; 77: 769-70.
  47. Xia T, Wang Y. Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome. Am J Transplant, 2020.
  48. Xu JJ, Samaha D, Mondhe S, Massicotte-Azarniouch D, Knoll G, Ruzicka M. Renal infarct in a COVID-19-positive kidney-pancreas transplant recipient. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020.
  49. Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020: 1916-21.
  50. Abrishami A, Samavat S, Behnam B, Arab-Ahmadi M, Nafar M, Sanei Taheri M. Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients. Eur Urol. 2020; 78: 281-6.
  51. Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020; 97: 1076-82.
  52. Bösch F, Börner N, Kemmner S, et al. Attenuated early inflammatory response in solid organ recipients with COVID-19. Clin Transplant. 2020: e14027.
  53. Bossini N, Alberici F, Delbarba E, et al. Kidney transplant patients with SARS-CoV-2 infection: the brescia renal COVID task force experience. Am J Transplant. 2020.
  54. Chen TY, Farghaly S, Cham S, et al. COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. Transpl Infect Dis. 2020: e13378.
  55. University C. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. J Am Soc Nephrol. 2020; 31: 1150-6.
  56. Crespo M, Pérez-Sáez MJ, Redondo-Pachón D, et al. COVID-19 in elderly kidney transplant recipients. Am J Transplant. 2020; May 29;10.1111/ajt.16096. doi: 10.1111/ajt.16096. Online ahead of print.
  57. Devresse A, Belkhir L, Vo B, et al. COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 22 Cases From Belgium. Kidney Med. © 2020 The Authors., 2020.
  58. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. Am J Transplant. 2020; 20: 1849-58.
  59. Fung M, Chiu CY, DeVoe C, et al. Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States. Am J Transplant. © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons., 2020.
  60. Maritati F, Cerutti E, Zuccatosta L, et al. SARS-CoV-2 infection in kidney transplant recipients: experience of the italian marche region. Transpl Infect Dis. 2020: e13377.
  61. Mehta SA, Leonard J, Labella P, et al. Outpatient management of kidney transplant recipients with suspected COVID-19-Single-center experience during the New York City surge. Transpl Infect Dis. 2020: e13383.
  62. Mella A, Mingozzi S, Gallo E, et al. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Transpl Infect Dis. © 2020 Wiley Periodicals LLC., 2020: e13348.
  63. Montagud-Marrahi E, Cofan F, Torregrosa JV, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients. Am J Transplant, 2020.
  64. Rodriguez-Cubillo B, Moreno de la Higuera MA, Lucena R, et al. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? Am J Transplant. 2020; Jun 12;10.1111/ajt.16141. doi: 10.1111/ajt.16141. Online ahead of print.
  65. Silva F, Cipriano A, Cruz H, et al. SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases. Transpl Infect Dis. 2020: e13394.
  66. Trujillo H, Caravaca-Fontán F, Sevillano Á, et al. SARS-CoV-2 Infection in Hospitalized Patients with Kidney Disease. Kidney Int Rep. 2020; 5: 905-9.
  67. Zhang H, Dai H, Xie X. Solid Organ Transplantation During the COVID-19 Pandemic. Front Immunol. 2020; 11: 1392.
  68. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol. 2020; 77: 748-54.
  69. Imam A, Abukhalaf SA, Imam R, Abu-Gazala S, Merhav H, Khalaileh A. Kidney Transplantation in the Times of COVID-19 - A Literature Review. Ann Transplant. 2020; 25: e925755.
  70. Esagian SM, Ziogas IA, Giannis D, Hayat MH, Elias N, Tsoulfas G. Challenges in Abdominal Organ Transplantation During the COVID-19 Pandemic. Front Med (Lausanne). 2020; 7: 287.
  71. Husain SA, Dube G, Morris H, et al. Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. Clin J Am Soc Nephrol. 2020.
  72. Lorenzo D’Antiga. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transplantation. 2020; 26: 832-4.
  73. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-62.
  74. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:458–464. DOI: http://dx.doi.org/10.15585/mmwr.mm6915e3.
  75. Lighter J, Phillips M, Hochman S, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020; 71: 896-7.
  76. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html, accessed online 6 September 2020
  77. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475-81.
  78. Hong Chu K, Kay Tsang W, S. Tang C, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney International. 2005; 67: 698-705.
  79. R. Tisoncik J, J. Korth M, P. Simmons C, J. Farrar, R. Martin T, G. Katze M. Into the Eye of the Cytokine Storm. Microbiology and Molecular Biology Reviews. 2012; 76: 16-32.
  80. Mombelli M, Kampouri E, Manuel O. Influenza in solid organ transplant recipients: epidemiology, management, and outcomes. Expert Rev Anti Infect Ther. 2020; 18: 103-12.
  81. M.L. Ritter, L. Pirofski. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transplant Infectious Disease. 2009; 11: 290-7.
  82. P. Berger S, Claudia Sommerer, Oliver Witzke, et al. Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. American Journal of Transplantation. 2019; 19: 3018-34.
  83. Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A. mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol . 2014;27(5):495-506. doi:10.1007/s40620-014-0103-y.
  84. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc. 2009; 41: 3796-9.
  85. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006; 44: 173-5.
  86. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531: 381-5.
  87. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.
  88. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56: 105949.
  89. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. https://wwwwhoint/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-/ritonavir-treatment-arms-for-covid-19 Published online 4/7/2020, last accessed 30/7/2020, WHO Website, 2020.
  90. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395: 683-4.
  91. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on dexamethasone https://wwwrecoverytrialnet/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19 Published online 16 June 2020, last accessed 30/7/2020.
  92. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2019; 25: e123-e7.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback